SCHEMBL4487194

SCHEMBL4487194

CCOC(=O)[C@@H]1CCC[C@@H]1NCCC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SSTR3 P32745 1/20 0.41
TAS1R3 Q7RTX0 2/20 0.39
TAS1R1 Q7RTX1 2/20 0.39
JAK1 P23458 1/20 0.39
CTSB P07858 1/20 0.36
HRH3 Q9Y5N1 1/20 0.34
CA12 O43570 2/20 0.33
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
FKBP1A P62942 2/20 0.33
CA9 Q16790 1/20 0.33
MAPT P10636 1/20 0.33
PKM P14618 1/20 0.33
ALDH1A1 P00352 2/20 0.32
MEN1 O00255 1/20 0.32
TSHR P16473 1/20 0.32
KMT2A Q03164 1/20 0.32
KDM4E B2RXH2 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4499466 1.00 SSTR3 (0.41) SSTR3TAS1R3TAS1R1JAK1CTSB
SCHEMBL4485499 1.00 SSTR3 (0.41) SSTR3TAS1R3TAS1R1JAK1CTSB
SCHEMBL4485497 1.00 SSTR3 (0.41) SSTR3TAS1R3TAS1R1JAK1CTSB
SCHEMBL4485502 1.00 SSTR3 (0.41) SSTR3TAS1R3TAS1R1JAK1CTSB
SCHEMBL4480915 0.97 SSTR3 (0.44) SSTR3TAS1R3TAS1R1JAK1CTSB
SCHEMBL4480911 0.97 SSTR3 (0.44) SSTR3TAS1R3TAS1R1JAK1CTSB
SCHEMBL4480919 0.97 SSTR3 (0.44) SSTR3TAS1R3TAS1R1JAK1CTSB
SCHEMBL4485200 0.84 TAS1R3 (0.40) TAS1R3TAS1R1JAK1CTSBHRH3
SCHEMBL4489932 0.84 TAS1R3 (0.40) TAS1R3TAS1R1JAK1CTSBHRH3
SCHEMBL4485203 0.84 TAS1R3 (0.40) TAS1R3TAS1R1JAK1CTSBHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7582626-B2 5,6-dihydro-1H-pyridin-2-one compounds ANADYS PHARMACEUTICALS, INC. (US) 2009-09-01 US disclosed
US-7582626-B2 5,6-dihydro-1H-pyridin-2-one compounds ANADYS PHARMACEUTICALS, INC. (US) 2009-09-01 US disclosed
US-7582626-B2 5,6-dihydro-1H-pyridin-2-one compounds ANADYS PHARMACEUTICALS, INC. (US) 2009-09-01 US disclosed
US-20090111798-A1 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. 2009-04-30 US disclosed
US-20090111798-A1 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. 2009-04-30 US disclosed
US-20090111798-A1 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. 2009-04-30 US disclosed
WO-2008073982-A2 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. (US) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111798-A1 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS HAVCR2, PYGL, HCCS SSTR3 4729/4885TAS1R3 4286/4885TAS1R1 4108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.